Vascular Biogenics Ltd. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (33)

View All

Latest Posts

About This Stock More About This Stock
Vascular Biogenics Ltd. Shares Climb Up On Positive Phase 3 Note
Article By: TickerTV
Friday, April 21, 2017 11:43 AM EDT
VBLT opened trading yesterday at $5.15 which was down from the previous day’s trading close of $5.20. VBLT closed trading yesterday at $5.20 and spiked up after market to $6.05, equivalent to a 16% increase from the closing price.
In this article: VBLT
Read
Provectus Biopharmaceuticals Concludes FDA Meeting For PV-10 Phase 3; Successful Completion Of AB Science's Futility Test For Masitinib
Article By: BioMedReports
Tuesday, February 10, 2015 5:59 AM EDT
Here is a look at some of the headlines for companies that made news in the healthcare sector on February 9, 2015.
In this article: ACHN, AKBS, AKR.L, AVXL, BIOC, BMRN, BSDM, CLDX, CBMG, CEMI, ENSG, GALE, ICUI, ISLT, IART, JUNO, LJPC, LFVN, MJNA, HTGC, NSPH, OREX, RDHL.TA, RCPT, RGLS, RNN, SBRA, WMGI, VBLT
Read
CERS Reports US Phase 2 Clinical Trial Of INTERCEPT Met Primary Endpoint; VBLT Announces Positive Phase 2a Data For VB-111
Article By: BioMedReports
Tuesday, December 23, 2014 8:18 AM EDT
CERS announced its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System. VBLT announced positive results from its exploratory Phase 2a study of VB-11.
In this article: CERS, VBLT
Read
All Posts

Latest Tweets for $VBLT

No tweets yet!

PARTNER HEADLINES